Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05061550
Title	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)
Acronym	NeoCOAST-2
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Durvalumab + Monalizumab Durvalumab + Oleclumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ITA \| IRL \| HUN \| FRA \| ESP \| CAN \| BEL